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Rotavirus is the leading cause of severe childhood gastroenteritis. Each year, rotavirus is 
responsible for about 25 million clinic visits, two million hospital admissions, and 180 000–
450 000 deaths in children under 5 years of age globally.1–3 Although rotavirus infection is 
prevalent worldwide, most deaths from this infection occur in developing countries (fig 1). 
Gastroenteritis caused by rotavirus cannot be clinically distinguished from that caused by 
other enteric pathogens; diagnosis requires testing of fecal specimens with commercially 
available assays. However, rotavirus is not routinely tested for in patients with gastroenteritis 
because the results do not alter clinical management, which relies mainly on appropriate 
rehydration therapy. Orally administered live attenuated vaccines that mimic natural 
infection offer the best protection against rotavirus. Two licensed rotavirus vaccines have 
been available since 2006 and have been implemented in many countries. We review 
approaches to diagnosis, management, and prevention of rotavirus gastroenteritis.
How does rotavirus gastroenteritis present clinically?
The clinical spectrum of rotavirus infection ranges from subclinical illness or mild watery 
diarrhea of limited duration to frequent profuse diarrhea with vomiting and fever that can 
result in dehydration with shock, electrolyte imbalance, and death. Rotavirus illness usually 
begins with acute onset of fever and vomiting, followed one or two days later by frequent 
watery stools. About 30–40% of children may have a moderate fever (temperature >39°C). 
Vomiting usually lasts for only one or two days and other gastrointestinal symptoms 
generally resolve in three to seven days.
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Although gastroenteritis is the chief manifestation of rotavirus infection, neurologic features
—including benign convulsions (usually afebrile but febrile in some cases), encephalitis or 
encephalopathy, and cerebellitis—have also been described.4 For example, a multicentre 
study from Canada reported that 7% of 1359 children admitted to hospital with laboratory 
confirmed rotavirus had seizures at presentation.5 A variety of other clinical conditions (such 
as sudden infant death syndrome, necrotizing enterocolitis, intussusception, Kawasaki’s 
disease, and type 1 diabetes) have been associated with rotavirus gastroenteritis, but a causal 
association has not been confirmed. A transient rise in serum transaminase concentrations is 
also often seen in patients with rotavirus gastroenteritis.
Who gets rotavirus disease?
Rotavirus infects nearly all children in developed and developing countries by 3–5 years of 
age. Neonatal infections occur but are often asymptomatic or mild, possibly because of 
protection from maternal antibody. The incidence of clinical illness peaks in children aged 
4–23 months, who are also at greatest risk of severe disease that requires hospital admission. 
Although repeat infections are common (three or more rotavirus infections occurred in about 
42% of children by 2 years of age in one follow-up study in a cohort of Mexican children), 
symptoms are milder with each subsequent infection.67 Therefore, rotavirus infections are 
usually subclinical or mild in adults, but they can be severe, particularly in 
immunocompromised and older people.8 Rotavirus is also an important cause of nosocomial 
diarrhea.
Case-control studies in industrialized countries have shown that lack of breast feeding, 
prematurity, and low birth weight are associated with increased risk of hospital admission 
for rotavirus gastroenteritis.910 Protracted rotavirus diarrhea with prolonged viral excretion 
and, in rare instances, systemic dissemination has been described in severely 
immunodeficient children, particularly those with severe T cell and combined T and B cell 
deficiencies. People who are immunosuppressed in preparation for bone marrow 
transplantation are also at risk for severe or even fatal rotavirus disease.
In all regions of the world, rotavirus is the leading cause of hospital admission for 
gastroenteritis. A systematic review of 131 surveillance studies published from 2001 to 2011 
found that rotavirus accounted for 33–49% of hospital admissions for gastroenteritis in 
countries in different geographic regions and with varying levels of child mortality.2 
However, more than 90% of global deaths from rotavirus occur in low income countries in 
sub-Saharan Africa and South Asia, mainly because of suboptimal access to healthcare, 
including basic hydration therapy. In addition, compared with industrialized countries, 
severe rotavirus gastroenteritis occurs at a younger age in developing countries (up to two 
thirds of all paediatric disease occurs in the first year of life) and coinfections with other 
enteric pathogens are more common.
Summary points
Rotavirus is the leading cause of severe gastroenteritis in children worldwide, 
accounting for 35–40% of hospital admissions for gastroenteritis
Parashar et al. Page 2
BMJ. Author manuscript; available in PMC 2018 January 22.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Each year, 180 000–450 000 children under 5 years die from rotavirus 
gastroenteritis, with more than 90% of deaths occurring in developing countries
Because nearly all children are affected by rotavirus by age 5 years, good 
sanitation and hygiene alone are inadequate for prevention
Orally administered live attenuated vaccines offer the best protection against 
rotavirus; as of December 2013, national immunization programs of 51 countries 
include rotavirus vaccine
Such programs have greatly reduced morbidity and mortality from gastroenteritis
A low risk of intussusception has also been documented post-licensure in some 
countries, but this risk is greatly exceeded by the health benefits of vaccination
Sources and selection criteria
We looked at recent conference proceedings and searched PubMed, the Cochrane 
Database of Systematic Reviews, and Clinical Evidence online using the terms 
“rotavirus”, “rotavirus gastroenteritis”, and “rotavirus vaccines”. We focused on 
systematic reviews, meta-analyses, and high quality randomized controlled trials 
published in English within the past 10 years (2004–13).
In temperate climates, rotavirus gastroenteritis shows prominent seasonality, occurring 
mainly during the fall and winter, with little disease activity during summer months.11 In 
tropical countries, rotavirus occurs all year round, although incidence often increases during 
the cool dry months.
How do rotaviruses cause diarrhea?
Mechanisms of rotavirus pathogenesis have been studied in animal models and humans. The 
infectious dose of rotavirus is estimated to be 100–1000 viral particles.12 Transmission of 
rotavirus occurs mainly through the fecal-oral route, and viral spread can occur through 
contaminated hands, environmental surfaces and objects, and occasionally food and water. 
Rotavirus exclusively infects the mature differentiated enterocytes found at the tips of the 
villi in the small intestine (fig 2). Attachment of rotavirus to its sialoglycoprotein and 
integrin receptors is mediated mainly by viral protein 4 (VP4), but neutralizing antibodies 
directed against VP4 or VP7 (or both) can prevent viral binding and penetration. Infection of 
the enterocyte leads to virus entry, uncoating of the virus, transcription of nucleic acid, 
translation of viral proteins, formation of viroplasms, and apical release of the virus and 
viral protein by a non-classic secretory pathway.13 The progeny virus are produced after 10–
12 hours and released in large numbers into the intestinal lumen. Rotavirus can infect 
neighboring cells, leading to continued replication and shedding, which consists initially of a 
high viral load. In children, the viral load decreases rapidly as diarrhea resolves, but viral 
nucleic acid can be detected at low levels for several weeks.14
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The pathogenesis of rotavirus diarrhea includes effects on absorption and on secretion. 
Morphologically, rotavirus infection causes enterocyte death and desquamation, leading to 
the loss of absorptive villous cells and the proliferation of secretory crypt cells.15 
Malabsorption may also result from a virus induced reduction in the expression of absorptive 
enzymes, as well as paracellular leakage as a consequence of functional changes in tight 
junctions between enterocytes, which may be mediated by the viral non-structural protein 4 
(NSP4). Biopsies show atrophy of the villi and mononuclear cell infiltrates in the lamina 
propria. Increased chloride secretion and loss of consequent water and electrolyte are 
mediated by NSP4, which acts as a viral enterotoxin, activating cellular calcium channels 
and inducing secretory diarrhea. Activation of the enteric nervous system (also thought to be 
dependent on NSP4) induces secretory diarrhea and increases intestinal motility.13 Villous 
brush border enzymes such as sucrase and isomaltase also decrease, resulting in 
accumulation of undigested sugars in the intestinal lumen. This increases the osmotic 
gradient, which in turn favours further fluid secretion.
Rotavirus infection was previously thought to be limited to the intestine, but several studies 
over the past decade have shown that rotavirus causes short term viremia in 
immunocompetent infants as well as in experimentally infected animals.16 The clinical 
relevance of this systemic spread of rotavirus remains unclear, but it may be linked to the 
extraintestinal clinical manifestations associated with rotavirus infection.
How is rotavirus diagnosed?
Rotavirus can be detected in stool specimens from children with gastroenteritis by several 
techniques, including electron microscopy, polyacrylamide gel electrophoresis, antigen 
detection assays, reverse transcription polymerase chain reaction (RT-PCR), and virus 
isolation. Diagnosis of rotavirus was initially by electron microscopy, with and without 
agglutination by immune sera. Large numbers of rotavirus particles (up to 1011/g feces) are 
excreted during the acute phase of infection, and children with severe diarrhea seem to 
excrete a greater number of viruses.17 Polyacrylamide gel electrophoresis detects rotavirus 
RNA extracted directly from stool specimens; the electrophoretic migration pattern of the 11 
segments of the double stranded RNA genome permits analysis of the relatedness of 
circulating strains.18
Children with gastroenteritis are not routinely tested for rotavirus because the results do not 
alter treatment. When testing is performed, antigen detection tests—including commercially 
available enzyme linked immunosorbent assays (ELISAs) and immunochromatographic 
assays—are widely used. Most of these tests have high sensitivity and specificity (90–95%).
19
 RT-PCR is widely used in research laboratories to detect the viral genome.20 It provides 
data on the VP7 and VP4 genotypes that form the basis of binary classification (G and P 
type, respectively) of rotavirus strains.
How is rotavirus gastroenteritis treated?
The management of acute rotavirus gastroenteritis focuses on the treatment and prevention 
of dehydration. In most situations the clinician will not be aware at the start of treatment 
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whether the gastroenteritis is caused by rotavirus or another pathogen. Initial assessment 
therefore focuses on determining the degree of dehydration because this will be used to 
guide and monitor treatment.
Many evidence based reviews and clinical guidelines are available on various aspects of the 
assessment and treatment of acute gastroenteritis in young children.21–36 However, a recent 
systematic review of eight guidelines noted considerable variation in their quality, 
inconsistencies between the recommendations, lack of evidence for many recommendations, 
and lack of generalisability to general practice.37 These were suggested as possible reasons 
why adherence to such guidelines is poor in high income countries. For example, the authors 
noted that in general practice it was unclear “how” or to “whom” oral rehydration therapy 
should be given. They concluded that future studies, particularly in general practice, need to 
determine the value of clinical signs and symptoms in assessing dehydration, the optimal 
dose of oral rehydration solution for each grade of dehydration, and the validity of reasons 
why clinicians prescribe other drugs. In contrast, another recent assessment of the quality of 
clinical practice guidelines for acute gastroenteritis, using the appraisal of guidelines for 
research and evaluation instrument, concluded that the overall quality of these guidelines 
was fair.38
How should dehydration be assessed?
Several scoring systems have been devised to assess dehydration.39 The World Health 
Organization scale is probably most widely used in the developing world (table 1),40 
whereas the modified four point Gorelick score (box) and clinical dehydration scale (table 2) 
have been used in developed world settings.32–3439 The clinical dehydration scale has been 
reported to help predict a longer length of stay and the need for intravenous fluid 
rehydration.32 It is generally accepted that conventional clinical signs of dehydration are 
valid and reliable when used collectively but individually they lack sensitivity and 
specificity.41 The Vesikari and Clark scores are used in rotavirus vaccine efficacy trials for 
assessing the severity of gastroenteritis but are not designed to guide clinical management 
according to the degree of dehydration.35
Oral and intravenous rehydration therapy
Oral and intravenous rehydration is the mainstay of treatment for rotavirus and other causes 
of acute gastroenteritis. Oral rehydration therapy is the preferred treatment of mild to 
moderate dehydration in children with acute diarrhea.272941 For every 25 children (95% 
confidence interval 14 to 100) treated one will not respond and will require intravenous 
rehydration.27 Expert consensus recommends that children who are very ill, lethargic, 
drinking poorly, or have shock or near shock are initially treated intravenously. Oral 
rehydration therapy should not be given to children with intestinal ileus until bowel sounds 
are audible, or in the presence of glucose malabsorption.29
For more than two decades, WHO recommended the standard glucose based oral 
rehydration solution (90 mmol/L sodium, 111 mmol/L glucose, and a total osmolarity 311 
mmol/L).28 However, subsequent studies have shown that when compared with the standard 
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WHO solution, reduced osmolarity oral rehydration solution is associated with fewer 
unscheduled intravenous fluid infusions (odds ratio 0.59, 0.45 to 0.79), lower stool volume 
after randomization, less vomiting, and no increased risk of hyponatremia.28 In 2002, WHO 
recommended the routine use of a solution with reduced osmolarity (sodium 75 mmol/L, 
glucose 75 mmol/L, and total osmolarity 224 mmol/L) for non-cholera diarrhea.
To maintain hydration of children with “no signs of dehydration,” WHO recommends giving 
extra fluid or oral rehydration solution after each loose stool. The suggested volume is 50–
100 mL (quarter to half a large cup) for children under 2 years of age and a 100–200 mL 
(half to one large cup) for those above 2.40 For children with “some signs of dehydration,” 
WHO recommends correcting hydration over four hours with 75 mL/kg of solution.40 
However, a review of eight international guidelines showed that recommendations on the 
dose of oral rehydration solution were not evidence based and were inconsistent, reflecting 
the use of expert opinion and differences in how guidelines categorized dehydration.37 The 
authors concluded that the optimal regimen was unclear.
It is important that breast feeding should continue throughout the rehydration and 
maintenance phases of treatment.40 Feeding should be restarted as soon as possible because 
this will reduce the duration and severity of diarrhea, and there is no evidence that early 
refeeding increases the risk of unscheduled intravenous fluid use, episodes of vomiting, or 
development of persistent diarrhea.22 Although lactose-free feeds may reduce the duration of 
diarrhea in children with mild to severe dehydration compared with feeds containing lactose, 
there is no evidence that lactose containing feeds are harmful for most children with acute 
gastroenteritis.42
Randomized controlled trials—including some that specifically assessed efficacy against 
rotavirus gastroenteritis—have shown that other treatments such as probiotics, zinc, 
ondansetron, nitazoxanide, and some biological compounds are effective in the management 
of acute gastroenteritis.21232440–45 However, recommendations for the use of these 
treatments vary considerably between different developmental regions and different 
countries, and further discussion of their use is beyond the scope of this article.
How can rotavirus gastroenteritis be prevented?
Because rotavirus infects nearly all children in both industrialised and developing countries 
early in life, good hygiene and sanitation alone are considered inadequate for prevention. 
Observational studies have shown that breast feeding confers protection from rotavirus 
gastroenteritis, although one case-control study indicated that it may only postpone the 
occurrence of rotavirus gastroenteritis to the post-weaning period.46
Follow-up of birth cohorts indicates that, although children can be infected with rotavirus 
four to five times in the first two years of life, the incidence of severe rotavirus 
gastroenteritis is reduced with each repeat infection.67 Therefore, orally administered, live, 
attenuated rotavirus vaccines have been developed to mimic the effect of natural infection 
and prevent severe rotavirus disease.
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A rhesus-human reassortant rotavirus vaccine (Rotashield, Wyeth) was licensed in the US in 
1998 after showing high efficacy against severe rotavirus gastroenteritis in randomized 
clinical trials.47 Rotashield was recommended for routine immunization of US infants the 
same year but was abruptly withdrawn a year later because post-licensure observational 
studies found that it was associated with a severe adverse event, intussusception.4849 
Intussusception is a form of bowel obstruction that often requires surgery and is associated 
with high fatality if not treated. It was estimated that vaccination of 10 000 infants with 
Rotashield resulted in one excess case of intussusception.
Four point modified Gorelick score3334
1 point for each of the signs listed below:
• Ill general appearance
• Absent tears
• Dry mucous membranes
• Capillary refill >2 s
≤1 points: maintain hydration (<5% dehydration).
2 points: needs oral rehydration (5–10% dehydration).
3–4 points with normal vital signs: needs intravenous rehydration (>10% dehydration).
Abnormal vital signs (increased heart rate, decreased blood pressure, decreased level of 
consciousness, increased capillary refill time): needs resuscitation.
Two other live oral rotavirus vaccines—a pentavalent bovine-human reassortant vaccine 
(RotaTeq, Merck) and a monovalent human vaccine (Rotarix, GSK Biologicals)—were in 
advanced stages of clinical testing when Rotashield was withdrawn (table 3). RotaTeq and 
Rotarix were each tested in randomized clinical trials of 60 000–70 000 infants to assess the 
risk of intussusception before licensure.5051 No increase in risk was found during the 42 and 
30 days post-vaccination after the three doses of RotaTeq or two doses of Rotarix, 
respectively. The vaccines showed 85–98% efficacy against severe rotavirus gastroenteritis 
in these trials conducted in the Americas and Europe, with good protection against disease 
caused by rotavirus strains not included in the vaccines (heterotypic immunity). These 
findings supported vaccine licensure and recommendations for use by policy groups in the 
US and Europe and by WHO.52
As of December 2013, 51 countries include rotavirus vaccines in their national 
immunization programs. A systematic review of ecologic studies from eight countries 
reported a 49–89% decline in laboratory confirmed rotavirus hospital admissions and 17–
55% reduction in all cause hospital admissions for gastroenteritis in children under 5 years 
within two years of vaccine introduction.53 Unexpectedly, rotavirus vaccination of young 
infants has also resulted in decreases in rotavirus disease in children who missed 
vaccination, older children, and even adults who were not eligible for vaccination.54 This 
phenomenon, known as herd protection, is probably related to reduced transmission of 
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rotavirus in the community as a result of vaccination. Reductions in nosocomial rotavirus 
infections have also been seen since the introduction of the vaccine.55 Lastly, ecologic 
studies from Mexico and Brazil have shown a 35% and 22% decline in childhood deaths 
from diarrhea, respectively, since the introduction of the vaccine,5657 and these reductions 
have been sustained for four years in Mexico. These findings are particularly noteworthy 
because vaccine efficacy against death from diarrhea was not evaluated in pre-licensure 
trials.
Post-licensure observational studies in several countries, including the US, Australia, 
Mexico, and Brazil, have also identified a low risk of intussusception with both rotavirus 
vaccines.58–65 The evidence of risk for the two vaccines is difficult to compare directly 
because the study populations and designs differed. In general, the overall risk is one to five 
excess cases of intussusception per 100 000 vaccinated infants. Considering the substantial 
and well documented health benefits of vaccination against this low intussusception risk, 
policy makers in countries with documented risk, as well as global health authorities such as 
WHO, strongly support rotavirus vaccination of infants.
Live oral vaccines against many diseases, such as polio, typhoid, and cholera, have 
performed less well in developing countries than in industrialised ones. The reasons for this 
variability are not completely understood. Potential explanations include interference in 
vaccine uptake by greater levels of maternal antibody or concurrent enteric infections in 
developing countries, as well as reduced immune response in infants because of 
comorbidities or malnutrition, including micronutrient deficiencies.66
Because of these concerns, randomised efficacy trials of both RotaTeq and Rotarix were 
conducted in developing countries in Africa and Asia.67–69 These trials showed modest 
vaccine efficacy (50–64%) against severe rotavirus gastroenteritis. Despite this reduced 
efficacy, the public health benefits of vaccination in terms of number of severe rotavirus 
gastroenteritis episodes prevented per 100 infants was greater in developing than in 
industrialised countries. This is because of the substantially greater rate of severe rotavirus 
gastroenteritis in developing countries. These considerations led WHO to issue a global 
recommendation for vaccination in 2009 and have prompted several low income countries to 
include rotavirus vaccination in their immunization programs.
As rotavirus vaccines are introduced into immunization programs of low income countries 
globally, it will be important to assess the real world impact of vaccination to gain a better 
understanding of vaccine effectiveness and safety in a range of settings. Although both of 
the licensed rotavirus vaccines have shown good protection against a range of circulating 
rotavirus strains, including strains with either or both G and P types not contained in the 
vaccine, further monitoring of the long term impact of vaccination on strain ecology is vital. 
Also, given the moderate efficacy of rotavirus vaccines in low income countries, 
interventions to improve vaccine performance (such as additional vaccine doses or different 
vaccination schedules) should be considered and evaluated. Finally, to sustain global 
implementation of vaccination, an adequate supply of affordable rotavirus vaccines must be 
assured. It is therefore encouraging that several manufacturers in emerging markets, 
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including India, China, Indonesia, and Brazil, are developing candidate rotavirus vaccines 
that may be available within the next five years.
Areas for future research
Exploring the role of rotavirus in extraintestinal clinical syndromes (such as 
neurologic manifestations, necrotizing enterocolitis)
Investigating the value of clinical signs and symptoms in assessing dehydration, 
particularly in general practice
Defining the optimal dose of oral rehydration solution for each grade of 
dehydration, so that consistent recommendations can be made
Identifying treatments (including antiviral agents) with clinical efficacy against 
rotavirus gastroenteritis
Community based action research and sociocultural research on knowledge, 
attitudes, perceptions, cultural practices, and health seeking behaviours with 
regard to rotavirus infection
Understanding the benefit-risk profile of routine rotavirus vaccination in a diverse 
range of geographic and socioeconomic settings
Investigating the effectiveness and impact of rotavirus vaccination in low income 
settings
Identifying interventions (such as additional vaccine doses or alternate schedules, 
supplementation with micronutrients) or alternative approaches (such as parenteral 
vaccines) that might improve the performance of rotavirus vaccines in low income 
settings
Additional educational resources
Resources for healthcare professionals
Centers for Disease Control and Prevention. Prevention of rotavirus gastroenteritis 
among infants and children—recommendations of the Advisory Committee on 
Immunization Practices (ACIP). MMWR 2009;58(RR02):1–25. www.cdc.gov/
mmwr/preview/mmwrhtml/rr5802a1.htm (free access)
WHO. WHO position paper on rotavirus vaccines. Wkly Epidemiol Rec 
2013;88:49–64. www.who.int/wer/2013/wer8805.pdf (free access)
Soares-Weiser K, MacLehose H, Bergman H, Ben-Aharon I, Nagpal S, Goldberg 
E, et al. Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane 
Database Syst Rev 2012;11:CD008521 (subscription required)
PATH (http://sites.path.org/rotavirusvaccine/rotavirus-advocacy-and-
communications-toolkit/)—Free rotavirus disease and vaccine resources
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PATH (http://sites.path.org/rotavirusvaccine/current-issue-of-rotaflash-jpg/)—
Breaking news and updates on rotavirus vaccines
Resources for patients and parents
Centers for Disease Control and Prevention at (www.cdc.gov/rotavirus/index.html)
—Basic information on the symptoms, treatment, and prevention of rotavirus 
gastroenteritis
Tips for non-specialists
All children are infected with rotavirus in the first 3–5 years of life, regardless of 
hygiene and sanitation conditions
Vaccines are therefore the most effective way to prevent rotavirus diarrhea
Treatment of rotavirus diarrhea relies on hydration therapy
Rotavirus vaccines have performed well in countries where they are used 
routinely; in some settings, they have conferred additional benefits to unvaccinated 
children and adults through herd protection
Although rotavirus vaccines work less well in developing countries, the potential 
to prevent severe disease and deaths is greater because of the high disease burden 
in these settings
The documented health benefits of rotavirus vaccines far outweigh the small risk 
of intussusception that has been seen in some settings
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Fig 1. 
World Health Organization estimates of rotavirus mortality (deaths/100 000 children under 5 
years of age) by country in 2008. Reproduced, with permission, from Lancet Infectious 
Diseases2
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Fig 2. 
Mechanisms of rotavirus pathogenesis. Most information on rotavirus pathogenesis is 
derived from small animal models. Infection leads to attachment of the rotavirus to 
enterocytes (1), uncoating of the virus (2), followed by transcription and translation of viral 
proteins (3). This leads to the formation of a viroplasm, from which double layered particles 
assemble (4) and acquire outer coat proteins to form triple layered mature particles, which 
are shed by a non-classical secretory pathway (5). The viral enterotoxin non-structural 
protein 4 (NSP4; red triangles) is also released with the mature virions. NSP4 induces the 
release of intracellular calcium (Ca2+) (6) from the endoplasmic reticulum (ER) and disrupts 
tight junctions (7), resulting in paracellular leakage of fluid and electrolytes. NSP4 can act 
on crypt cells to induce chloride (Cl−) secretion directly (8) or through the enteric nervous 
system (ENS) (9), both of which draw water into the lumen. A decrease in brush border 
enzymes induced by infection (10) results in accumulation of sugars in the lumen and 
osmotic fluid loss. Destruction of intestinal cells later in infection results in loss of surface 
area and a malabsorptive diarrhea (11)
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Table 1
World Health Organization guidelines for assessing dehydration in children with acute gastroenteritis40
A B C
Condition*
Well, alert Restless, irritable Lethargic or unconscious
Eyes†
Normal Sunken Sunken
Thirst
Drinks normally, not thirsty Thirsty, drinks eagerly Drinks poorly, or not able to drink
Skin pinch‡
Skin goes back quickly Skin goes back slowly Skin goes back very slowly
Decision
No signs of dehydration Some dehydration if there are ≥2 signs in B Severe dehydration if there are ≥2 signs in C
*
Being lethargic and sleepy are not the same. A lethargic child is not simply asleep: the child’s mental state is dull and the child cannot be fully 
awakened; the child may appear to be drifting into unconsciousness.
†
In some infants and children the eyes normally appear somewhat sunken. It is helpful to ask the mother if the child’s eyes are normal or more 
sunken than usual.
‡
The skin pinch is less useful in infants or children with marasmus or kwashiorkor, and in obese children.
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Table 2
Clinical dehydration scale32
Characteristic Score*
0 1 2
General appearance Normal Thirsty, restless, or sleepy; irritable when touched Drowsy, limp, and cold; may be comatose
Eyes Normal Slightly sunken Deeply sunken
Tongue Moist Sticky Dry
Tears Present Decreased Absent
*
Total score: 0=no dehydration; 1–4=some dehydration; 5–8=moderate/severe dehydration.
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Table 3
Features of Rotarix and RotaTeq rotavirus vaccines
Feature Rotarix RotaTeq
Composition Single human rotavirus strain (P1A[8], G1) Five human G/P reassortants with bovine rotavirus strain 
WC3 (P7[5], G6): G1 × WC3; G2 × WC3; G3 × WC3; G3 
× WC3; P1A[8] × WC3
Number of doses 
needed
2 oral doses 3 oral doses
Schedule* Dose 1: minimum 6 weeks of age; dose 2: ≥4 weeks 
later; complete by 24 weeks of age
Dose 1: 6–12 weeks of age; doses 2 and 3: 4–10 week 
intervals; complete by 32 weeks of age
Dose Each dose (1–1.5 mL) contains at least 106 median cell 
culture infectious doses
Each dose (2 mL) contains at least 2.0–2.8×106 infectious 
units per reassortant
Shelf life 36 months 24 months
Storage 2–8°C, protected from light 2–8°C, protected from light
Contraindications History of hypersensitivity to the vaccine or any 
component of the vaccine; history of uncorrected 
congenital malformation of the gastrointestinal tract 
that would predispose to intussusception; history of 
severe combined immunodeficiency disease; history of 
intussusception
History of hypersensitivity to the vaccine or any 
component of the vaccine; history of severe combined 
immunodeficiency disease; history of intussusception
*Ages for vaccine doses vary according to the recommendations of individual countries and vaccination schedules.
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